JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB200966

HRP Anti-Lambda Light chain antibody [EPR5367-62]

Be the first to review this product! Submit a review

|

(4 Publications)

Rabbit Recombinant Monoclonal LV151 antibody - conjugated to HRP. Suitable for IHC-P, WB and reacts with Human samples. Cited in 4 publications.

View Alternative Names

Immunoglobulin lambda variable 1-51, Ig lambda chain V-I region BL2, Ig lambda chain V-I region EPS, Ig lambda chain V-I region NEW, Ig lambda chain V-I region NIG-64, IGLV1-51

3 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Lambda Light chain antibody [EPR5367-62] (AB200966)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Lambda Light chain antibody [EPR5367-62] (AB200966)

Negative IHC image of Lambda Light chain staining in a section of formalin-fixed paraffin-embedded normal human cerebral cortex, performed on a Leica BOND™. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab200966, 1/2500 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Lambda Light chain antibody [EPR5367-62] (AB200966)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Lambda Light chain antibody [EPR5367-62] (AB200966)

IHC image of Lambda Light chain staining in a section of formalin-fixed paraffin-embedded normal human tonsil*, performed on a Leica BOND™. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab200966, 1/2500 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

Western blot - HRP Anti-Lambda Light chain antibody [EPR5367-62] (AB200966)
  • WB

Lab

Western blot - HRP Anti-Lambda Light chain antibody [EPR5367-62] (AB200966)

This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab200966 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

All lanes:

Western blot - HRP Anti-Lambda Light chain antibody [EPR5367-62] (ab200966) at 1/5000 dilution

Lane 1:

Tonsil (Human) Whole Cell Lysate - adult normal tissue at 10 µg

Lane 2:

Human Plasma Total Protein Lysate at 10 µg

Lane 3:

Spleen (Human) Tissue Lysate - adult normal tissue at 10 µg

Predicted band size: 23 kDa

Observed band size: 28 kDa

false

  • Unconjugated

    Anti-Lambda Light chain antibody [EPR5367-62]

  • Carrier free

    Anti-Lambda Light chain antibody [EPR5367-62] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR5367-62

Isotype

IgG

Conjugation

HRP

Excitation/Emission
Carrier free

No

Reacts with

Human

Applications

WB, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/2500", "IHCP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/5000", "WB-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.1% Proclin 300 Solution Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Lambda Light Chain also known as lambda chain or lambda protein forms a part of immunoglobulins (antibodies). Its mass typically ranges between 22 to 24 kDa. This protein is expressed primarily in B cells. Specifically it pairs with heavy chains to form the complete antibody molecule. It participates in the antigen recognition process supporting the immune system's defense mechanisms.
Biological function summary

Lambda Light Chain participates in immunological functions by contributing to the antigen-binding site of antibodies. It exists as a part of the immunoglobulin complex. The lambda chain alongside heavy chains forms the variable part of antibodies allowing specificity in antigen recognition. Its variation leads to a diverse antibody repertoire which is important for recognizing a wide range of pathogens.

Pathways

Lambda Light Chain fits into pathways involving adaptive immune responses. It is important in antigen processing and presentation pathways. In this context it interacts with the heavy chains which together drive the specificity and efficiency of immune response pathways. It also associates with proteins like the major histocompatibility complex (MHC) which facilitates antigen presentation to T cells.

Lambda Light Chain associates with multiple myeloma a cancer of plasma cells and light chain amyloidosis a disorder where light chains accumulate as amyloid fibrils in tissues. In these conditions proteins like immunoglobulin heavy chain and albumin often interact with or are affected by lambda chains providing insights into disease mechanisms and potential targets for therapeutic intervention.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed : 24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268).
See full target information IGLV1-51

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

International journal of molecular sciences 25: PubMed38999969

2024

Stability Engineering of Recombinant Secretory IgA.

Applications

Unspecified application

Species

Unspecified reactive species

Kathrin Göritzer,Richard Strasser,Julian K-C Ma

Molecular therapy : the journal of the American Society of Gene Therapy 32:689-703 PubMed38268188

2024

Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2.

Applications

Unspecified application

Species

Unspecified reactive species

Kathrin Göritzer,Elisabetta Groppelli,Clemens Grünwald-Gruber,Rudolf Figl,Fengfeng Ni,Huimin Hu,Yuncheng Li,Yalan Liu,Qinxue Hu,Rama Devudu Puligedda,Jae-Wan Jung,Richard Strasser,Scott Dessain,Julian K-C Ma

Proceedings of the National Academy of Sciences of the United States of America 120:e2217590120 PubMed37011197

2023

Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization.

Applications

Unspecified application

Species

Unspecified reactive species

Arman Izadi,Arsema Hailu,Magdalena Godzwon,Sebastian Wrighton,Berit Olofsson,Tobias Schmidt,Anna Söderlund-Strand,Elizabeth Elder,Sofia Appelberg,Maria Valsjö,Olivia Larsson,Vidar Wendel-Hansen,Mats Ohlin,Wael Bahnan,Pontus Nordenfelt

Science translational medicine 13: PubMed34011628

2021

Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.

Applications

Unspecified application

Species

Unspecified reactive species

Joanne Ng,Serena Barral,Carmen De La Fuente Barrigon,Gabriele Lignani,Fatma A Erdem,Rebecca Wallings,Riccardo Privolizzi,Giada Rossignoli,Haya Alrashidi,Sonja Heasman,Esther Meyer,Adeline Ngoh,Simon Pope,Rajvinder Karda,Dany Perocheau,Julien Baruteau,Natalie Suff,Juan Antinao Diaz,Stephanie Schorge,Jane Vowles,Lucy R Marshall,Sally A Cowley,Sonja Sucic,Michael Freissmuth,John R Counsell,Richard Wade-Martins,Simon J R Heales,Ahad A Rahim,Maximilien Bencze,Simon N Waddington,Manju A Kurian
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com